Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 11/20 | 0.43 |
| ▸ | CLK2 | P49760 | 9/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | CLK3 | P49761 | 7/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19336081 | 0.91 | CLK2 (0.44) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL19336058 | 0.91 | CLK2 (0.45) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL20179068 | 0.89 | WNT1 (0.42) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL20929836 | 0.88 | WNT1 (0.41) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL20179039 | 0.88 | WNT1 (0.42) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL20179061 | 0.87 | WNT1 (0.60) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL17564146 | 0.86 | CLK2 (0.53) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL17564166 | 0.86 | WNT1 (0.52) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL20179032 | 0.84 | WNT1 (0.45) | WNT1CLK2TGFBR1CLK3DYRK1A | |
| SCHEMBL19860557 | 0.84 | CLK2 (0.44) | WNT1CLK2TGFBR1CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885CLK2 2494/4885TGFBR1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.